Skip to content

Marriage of Synthetic Intelligence & Biology Spawns RNA-Focusing on Startup Atomic AI

The growth of disease-causing proteins is fertile searching floor for drug analysis. Many biotech startups are looking for small molecules able to binding to those targets. That is nice when it really works, however many protein targets stay elusive, stated Raphael Townsend, founder and CEO Atomic AI. Somewhat than pursue disease-causing proteins, Townsend’s startup goals for a unique goal: the RNA that carry directions for making these proteins. Atomic AI makes use of synthetic intelligence to search out methods to drug RNA and it is now out of stealth backed by $35 million.

“By concentrating on the RNA as an alternative, you are giving your self new methods of concentrating on these untreatable illnesses,” Townsend stated.

The Sequence A spherical of financing introduced Wednesday was led by Playground World.

To be able to drug RNA, scientists have to first get a greater understanding of it. Proteins are comparatively properly understood, with a whole lot of 1000’s of identified protein constructions, Townsend stated. By comparability, the human transcriptome, the entire set of all RNA, is poorly understood. The a whole lot of identified RNA constructions are much less properly mapped out in comparison with proteins, Townsend stated. That is key as a result of there’s rising recognition that RNA performs a significant function in illness by itself, he added.

Proteins fold and alter form, which may make them troublesome to hit with a small molecule. However RNA is considerably extra versatile making it extra of a transferring goal, Townsend stated. The know-how of San Francisco-based Atomic AI maps out the transcriptome with an method that mixes moist lab experiments with computational evaluation. Knowledge generated by the moist lab are used to coach the AI ​​to find novel targets on the three-dimensional construction of RNA, Townsend stated. The AI ​​makes predictions that inform further moist lab experiments. These outcomes feed further AI evaluation, persevering with a virtuous cycle.

Atomic AI’s know-how is predicated on analysis stemming from Townsend’s PhD work at Stanford College. That analysis was printed within the journal Science in 2021, the identical yr Atomic AI fashioned. Since then, the corporate has made advances with its algorithms and its moist lab, Townsend stated. The know-how, now known as Platform for AI-driven RNA Construction Exploration (PARSE) has additionally improved in pace and accuracy.

The brand new capital permits Atomic AI to scale the platform, enabling the startup to turn into a drug discovery group, Townsend stated. The corporate will start to slender down the targets it should pursue. Townsend declined to determine particular illnesses. Atomic AI might pursue, however he stated the know-how might be used to find small molecules to be used in oncology, neurodegenerative problems, cardiology, uncommon illness, and infectious illness. The startup’s preliminary analysis will concentrate on figuring out the components of the transcriptome which are even targetable, Townsend stated.

Atomic AI is not the primary biotech aiming to drug RNA, and along with having an earlier begin a few of these startups have already got partnerships with huge pharma firms. Essentially the most superior program of Arrakis Therapeutics is an oncology compound in lead optimization. The Waltham, Massachusetts-based firm has a drug discovery alliance with Roche. Skyhawk Therapeutics is one other Waltham-based firm creating RNA-targeting small molecules. That firm has alliances with Bristol Myers Squibb, Merck, and Takeda Pharmaceutical. Somewhat than instantly goal RNA, Remix Therapeutics is creating medicine that focus on components of the cell that course of it. Practically a yr in the past, the Cambridge, Massachusetts-based Remix inked a analysis alliance with a Johnson & Johnson subsidiary. Extra lately, Boulder, Colorado-based Arpeggio Biosciences unveiled a $17 million Sequence A spherical of funding.

Townsend acknowledges the opposite firms pursuing RNA-targeting small molecules, however he says what units Atomic AI aside is the moist lab part of its platform. Firms that take a purely AI method to RNA could have problem as a result of there’s simply not a lot RNA information on the market for these applied sciences to investigate, he defined.

Now that Atomic AI is out of stealth, Townsend stated he is on the lookout for potential partnerships. Whereas the startup’s inner analysis will concentrate on creating small molecule medicine, Townsend stated partnerships will concentrate on utilizing PARSE to develop new RNA-based medicines. The platform’s potential to foretell how RNA folds and kinds new constructions can be utilized to design new RNA medicines, he defined. The know-how additionally holds potential for bettering sure elements of RNA-based medicines, akin to stability. For instance, a extra secure RNA molecule might keep away from the ultra-cold storage required of the messenger RNA-based Covid-19 vaccines.

Atomic AI initially raised $7 million in a 2021 seed financing led by 8VC. That agency additionally invested within the Sequence A spherical, which included the participation of Manufacturing unit HQ; greylock; notboring; AME Cloud Ventures; and angel buyers together with former GitHub CEO Nat Friedman; Doug Mohr; Curai CEO Neal Khosla; and Patrick Hsu, a College of California, Berkeley professor, and Arc Institute co-founder.

Picture by libre de droit, Getty Photographs


Leave a Reply

Your email address will not be published. Required fields are marked *